The granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing talimogene laherparepvec (T-VEC) got the approval of the US food and drug administration (FDA) in 2015 to treat unresectable advanced melanoma [64,65,66]. This evidence concerns the gene CSF2 and melanoma.